Dear Editor,

In December 2019, cases of pneumonia associated with a novel 2019 coronavirus emerged in Wuhan (Hubei Province, China) \[[@CR1]\]. The causative agent was subsequently named SARS-CoV-2 and the resulting disease COVID-19. As of 17 March 2020, 80,894 cases of COVID-19 were reported in China of which 3237 (4%) were fatal. In Wuhan, 2490 (4.98%) of 50,005 cases died. In addition, 98,218 cases from 104 countries outside of China were laboratory-confirmed, of which 4189 (4.27%) were fatal. A previous study suggested that the condition of 11 (11%) patients worsened in a short period of time and they died of multiple organ failure \[[@CR2]\], while Wang et al. \[[@CR3]\] reported that 4.3% of COVID-19 cases were fatal. A national study of 1099 patients with COVID-19 found that 55 patients (5%) were admitted to an intensive care unit and 15 (1.36%) succumbed to the infection \[[@CR4]\]. It is important to emphasize that most patients studied previously were hospitalized and thus the full spectrum of COVID-19 severity is still being elucidated \[[@CR1]--[@CR4]\]. We aimed to further explore the clinicolaboratory characteristics, hospital complications and treatments of 25 fatal cases of COVID-19. The clinicolaboratory characteristics of survivors (*N* = 149) and non-survivors were also compared.

This was a single-center retrospective analysis. All consecutive fatal cases of COVID-19 admitted to Wuhan University Zhongnan Hospital from 3 January to 24 February 2020 were included. COVID-19 was confirmed using throat swab samples by real-time RT-PCR \[[@CR3], [@CR5]\]. Epidemiological, clinical and laboratory data as well as information on treatments received, hospital complications and causes of death were collected. Blood samples were collected at admission. The study was approved by the Ethics Committee of Wuhan University Zhongnan Hospital and informed consent was waived by the Ethics Committee.

Twenty-five fatal COVID-19 cases were included. The median age of these patients was 70 years (interquartile range \[IQR\] 64--80 years) and 19 (76%) were men. The median time from onset of symptoms to hospital admission and death was 7 days (IQR 1--10 days) and 19 days (IQR 13--26 days), respectively. As shown in Table [1](#Tab1){ref-type="table"}, fatal cases were older (70 years, IQR 64--80 years vs. 51 years, IQR 37--62 years), disproportionately male (76% vs. 40.3%) and more often suffered from comorbidities (64% vs. 24.2%; cardiovascular and cerebrovascular diseases: 32% vs. 7.4%) compared with non-fatal cases. Fatal cases were also more likely to be admitted to intensive care units (36% vs. 10.7%) and had higher medical expenses (53,745 CNY, IQR 30,286--112,268 CNY vs. 14,507 CNY, IQR 8813--27,617 CNY).Table 1Baseline characteristics and laboratory results of included cases of COVID-19Non-survivorsSurvivors*p*-value*N*25149--Age (years)70 (64--80)51 (37--62)\< 0.001Sex---male19 (76.0)60 (40.3)\< 0.001BMI (kg/m^2^)24.6 (22.3--28.3)23.6 (21.6--25.6)0.125Temperature at admission (°C)38.1 (37.1--39.0)38.0 (37.3--38.9)0.383Comorbidities Any16 (64.0)36 (24.2)\< 0.001 Hypertension12 (48.0)25 (16.8)\< 0.001 Diabetes6 (24.0)11 (7.4)0.010 Cardiovascular--cerebrovascular diseases8 (32.0)8 (7.4)\< 0.001 Respiratory diseases4 (16.0)8 (7.4)0.130Onset of symptom to (days) Hospital admission7 (1--10)7 (3--9)0.381 Death or discharge19 (13--26)20 (13--27)0.894ICU admission9 (36.0)16 (10.7)0.003Cost of hospitalization (CNY)53 745 (30 286--112 268)14 507 (8 813--27 617)\< 0.001Laboratory findings at admission^a^ White blood cell (10^9^/l)6.88 (4.96--13.48)4.22 (3.21--5.91)\< 0.001  Elevated (\> 9.5)10 (40.0)10 (6.7)\< 0.001 Lymphocyte (10^9^/l)0.53 (0.33--0.82)0.92 (0.67--1.23)\< 0.001  Reduced (\< 1.1 × 10^9^/l)23 (92.0)99 (66.4)0.010 IL-6 (pg/ml)108.8 (44.1--177.9)16.8 (4.4--76.9)\< 0.001  Elevated (\> 2.9 pg/ml)25 (100.0)115 (77.2)0.017 D-dimer (ng/ml)3306 (1790--7512)660 (370--1108)\< 0.001  Elevated (\> 500 ng/ml)24 (96.0)89 (59.7)\< 0.001 CRP (mg/l)118 (22--184)22 (6--45)\< 0.001  Elevated (\> 10 mg/l)25 (100.0)95 (63.8)\< 0.001Treatment Umifenovir3 (12.0)70 (47.0)0.001 Oseltamivir16 (64.0)61 (40.9)0.032 Lopinavir5 (20.0)46 (30.9)0.269 Methylprednisolone18 (72.0)71 (47.7)0.024 Noninvasive ventilation4 (16.0)5 (3.4)0.031 Invasive mechanical ventilation17 (68.0)2 (1.3)\< 0.001 ECMO3 (12.0)3 (2.0)0.052 CRRT7 (28.0)1 (0.7)\< 0.001Complications Shock and/or ARDS23 (92.0)8 (5.4)\< 0.001 Secondary bacterial infection20 (80.0)6 (4.0)\< 0.001 Acute cardiac injury^b^18 (72.0)7 (4.7)\< 0.001 Acute kidney injury19 (76.0)8 (5.4)\< 0.001 Acute liver injury15 (60.0)30 (20.1)\< 0.001Cause of death MODS14 (56.0)-- ARDS2 (8.0)-- Cardiac arrest5 (20.0)-- Respiratory failure4 (16.0)--The results were presented as median (IQR) for continuous variables and number (%) for categorical variables. The different characteristics between death and survival groups were tested by Mann--Whitney *U* test (continuous variables) or Chi-square test (categorical variables). A two-sided a of less than 0.05 was considered statistically significant*ICU* intensive care unit, *BMI* body mass index, *CNY*, China Yuan, *IL-6* interleukin-6, *CRP* C reaction protein, *ECMO* extracorporeal membrane oxygenation, *MODS* multiple organ dysfunction syndrome, *CRRT* continuous renal replacement therapy, *ARDS* acute respiratory distress syndrome^a^We calculated the average value if one patient had multiple tests^b^Acute cardiac injury was diagnosed if serum levels of cardiac biomarkers (e.g., troponin I) were above the 99th percentile upper reference limit, or new abnormalities were shown in electrocardiography and echocardiography

During the study period, 174 patients (all COVID-19-positive hospital admissions) had an outcome (death or discharge). Thus, the case fatality rate was 14.4% (95% CI 9.2--19.6%). The most common cause of death was multiple organ dysfunction syndrome (56%). Cardiac arrest (20%), respiratory failure (16%) and acute respiratory distress syndrome (16%) were other causes of death (Table [1](#Tab1){ref-type="table"}). Acute respiratory distress syndrome (shock), secondary bacterial infection and acute cardiac/kidney/liver injury were common during hospitalization. Most patients were treated with methylprednisolone (76%), invasive mechanical ventilation (68%) and oseltamivir (64%). Fatal cases experienced hospital complications and received aggressive treatment strategies more often than non-fatal cases (Table [1](#Tab1){ref-type="table"}). Interestingly, fatal cases were treated more often with oseltamivir and methylprednisolone, but less often with umifenovir (Table [1](#Tab1){ref-type="table"}).

Serum levels of interleukin-6, C-reactive protein and D-dimer were higher in non-survivors than in survivors, while lymphocyte counts were lower (Table [1](#Tab1){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}). Nearly, all fatal cases had abnormal coagulation, and 24 (96%) fatal cases showed elevated D-dimer levels. All fatal cases showed evidence of cytokine abnormalities and establishment of an inflammatory state as demonstrated by elevated interleukin-6 and C-reactive protein levels.Fig. 1Blood levels of biomarkers in non-survivors and survivors of COVID-19. **a** Levels of lymphocyte in non-survivors and survivors; **b** levels of interleukin-6 in non-survivors and survivors; **c** levels of C reaction protein in non-survivors and survivors; **d** levels of D-dimer in non-survivors and survivors. All data are medians and interquartile ranges (IQR), with dot plots representing all values

In summary, COVID-19 mortality is more common in older male patients with comorbidities and is mainly caused by multiple organ dysfunction syndrome. The roles of hypercoagulability and pathological inflammatory states should not be ignored. Similarly, other literature recently published in this population also showed that the increasing odds of in-hospital death associated with older age, the presence of underlying diseases, elevated inflammatory and d-dimer greater than 1 μg/ml on admission \[[@CR6], [@CR7]\].

An interferon-γ-related cytokine storm may be involved in immunopathological damage in SARS patients \[[@CR8]\]. In addition, SARS patients with early-stage disease, especially those with subsequent poor outcomes, had very high numbers of tumor necrosis factor-α- and interleukin-6-producing cells in the blood \[[@CR9]\]. Previous studies also reported that fatal cases of COVID-19 had higher levels of clotting factors and cytokines \[[@CR1]--[@CR3], [@CR7]\]. We speculate that the pathogenesis of fatal cases might involve uncontrolled release of immune mediators (i.e., a 'cytokine storm'). Ruan et al. \[[@CR6]\] also suggested that COVID-19 mortality might be due to virus-activated "cytokine storm syndrome" or fulminant myocarditis \[[@CR6]\]. Tocilizumab (a monoclonal antibody targeting the interleukin-6 receptor) had been used to treat cytokine storm syndrome \[[@CR10]\], and a clinical trial to assess its use in COVID-19 patients has been registered. These findings offer new insights into the characteristics of fatal cases of COVID-19, which may help identify patients at high risk of severe disease or death. The limitations of this study are listed in the supplementary material.
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